论文部分内容阅读
目的观察蚓激酶与弥可保联合治疗糖尿病周围神经病变的临床疗效。方法将68例2型糖尿病周围神经病患者随机分为治疗组和对照组,治疗组36例,对照组32例。治疗组给予口服百奥蚓激酶60万U,3次/天,同时应用弥可保500μg,肌肉注射,1次/天,连续2周。对照组应用弥可保500μg,肌肉注射,1次/天,连续2周。结果治疗14天后两组评分较前明显下降,但治疗组下降显著,治疗后两组平均评分有显著差异性(P<0.01)。结论表明百奥蚓激酶与弥可保联合治疗糖尿病周围神经病变安全有效,使糖尿病周围神经病变患者临床症状显著改善。
Objective To observe the clinical efficacy of lumbrokinase combined with methycobal in the treatment of diabetic peripheral neuropathy. Methods Sixty-eight patients with type 2 diabetic peripheral neuropathy were randomly divided into treatment group and control group, with 36 cases in treatment group and 32 cases in control group. The treatment group was given 600,000 U of orally administered Rubisco, 3 times a day, and 500μg of miconazole was administered intramuscularly once a day for 2 weeks. The control group was administered 500μg of miconazole, intramuscularly, once daily for 2 weeks. Results After 14 days of treatment, the scores of both groups decreased significantly, but the treatment group decreased significantly. After treatment, the average scores of two groups were significantly different (P <0.01). The conclusion shows that combination of lumbrokinase and methycobal is safe and effective in the treatment of diabetic peripheral neuropathy, and the clinical symptoms of patients with diabetic peripheral neuropathy are significantly improved.